TELIGENT, INC. (NASDAQ:TLGT) Files An 8-K Submission of Matters to a Vote of Security Holders

TELIGENT, INC. (NASDAQ:TLGT) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item 5.07.

Submission of Matters to a Vote of Security
Holders.

(a)On May 18, 2017, Teligent, Inc. (the Company)
held its 2017 Annual Meeting of Stockholders (the Annual
Meeting
). At the Annual Meeting, the holders of
48,586,331 shares of the Companys common stock were present in
person or represented by proxy, which represents 91.28% of the
total shares of outstanding common stock entitled to vote as of
the record date of March 30, 2017.

(b)The following actions were taken in the Annual Meeting:

(1) The following six nominees were reelected to serve on the
Companys Board of Directors (the Board)
until the Companys 2018 annual meeting of stockholders or
until their respective successors have been elected and
qualified, or until their earlier resignation or removal:
Name of Director Nominees Votes For Votes Withheld Broker Non-Vote
Jason Grenfell-Gardner 30,579,727 420,759 17,585,845
Bhaskar Chaudhuri 30,090,097 910,389 17,585,845
Steven Koehler 30,125,654 874,832 17,585,845
James C. Gale 30,121,831 878,655 17,585,845
John Celentano 30,092,227 908,259 17,585,845
Carole S. Ben-Maimon 30,124,355 876,131 17,585,845
(2) The selection of EisnerAmper LLP as the Companys independent
registered public accounting firm for the fiscal year ending
December 31, 2017, was ratified, based on the following
votes:
Votes For Votes Against Abstentions Broker Non-Vote
48,176,656 81,904 327,771
(3) The compensation of the Companys named executive officers, as
disclosed in our proxy statement, was approved by an advisory
vote, based on the following votes:
Votes For Votes Against Abstentions Broker Non-Vote
28,341,814 2,223,951 434,721 17,585,845


About TELIGENT, INC. (NASDAQ:TLGT)

Teligent, Inc., formerly IGI Laboratories, Inc., is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It has two platforms: developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its current contract manufacturing and formulation services business. Its pipeline includes over 30 Abbreviated New Drug Applications filed with the United States Food and Drug Administration for additional pharmaceutical products. It holds additional over 40 product candidates at various stages of its development pipeline, 10 of which are on stability testing.

TELIGENT, INC. (NASDAQ:TLGT) Recent Trading Information

TELIGENT, INC. (NASDAQ:TLGT) closed its last trading session down -0.03 at 8.64 with 130,149 shares trading hands.

An ad to help with our costs